| Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab D Baker, SS Herrod, C Alvarez-Gonzalez, G Giovannoni, K Schmierer JAMA neurology 74 (8), 961-969, 2017 | 223 | 2017 |
| Both cladribine and alemtuzumab may effect MS via B-cell depletion D Baker, SS Herrod, C Alvarez-Gonzalez, L Zalewski, C Albor, ... Neurology: Neuroimmunology & Neuroinflammation 4 (4), e360, 2017 | 140 | 2017 |
| MHC-class-II are expressed in a subpopulation of human neural stem cells in vitro in an IFNγ–independent fashion and during development B Vagaska, SEP New, C Alvarez-Gonzalez, F D’Acquisto, SG Gomez, ... Scientific reports 6 (1), 24251, 2016 | 58 | 2016 |
| A matter of identity—phenotype and differentiation potential of human somatic stem cells SEP New, C Alvarez-Gonzalez, B Vagaska, SG Gomez, NW Bulstrode, ... Stem cell research 15 (1), 1-13, 2015 | 48 | 2015 |
| Cord Blood Lin−CD45− Embryonic-Like Stem Cells Are a Heterogeneous Population That Lack Self-Renewal Capacity C Alvarez-Gonzalez, R Duggleby, B Vagaska, S Querol, SG Gomez, ... PloS one 8 (6), e67968, 2013 | 25 | 2013 |
| Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis KS Cesar Alvarez-Gonzalez, Ashok Adams, Joela Mathews, Benjamin P. Turner ... Ann Clin Transl Neurol, 2017 | 21 | 2017 |
| Treating the ineligible: disease modification in people with multiple sclerosis beyond NHS England commissioning policies Z Mao, C Álvarez-González, K Allen-Philbey, S De Trane, O Yildiz, ... Multiple Sclerosis and Related Disorders 27, 247-253, 2019 | 12 | 2019 |
| Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? Z Mao, C Álvarez-Gonzalez, S De Trane, O Yildiz, C Albor, G Doctor, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 4 (2 …, 2018 | 12 | 2018 |
| Factors associated with tobacco, alcohol, and other drug use among youth living in West Central Mexico O Campollo, P Sheikhattari, C Alvarez, J Toro-Guerrero, HS Avila, ... World Journal of Psychiatry 8 (1), 33, 2018 | 12 | 2018 |
| Fingolimod therapy in multiple sclerosis leads to the enrichment of a subpopulation of aged NK cells SC Schwichtenberg, A Wisgalla, M Schroeder-Castagno, ... Neurotherapeutics 18 (3), 1783-1797, 2021 | 9 | 2021 |
| Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017; 4 (4): e360 D Baker, SS Herrod, C Alvarez-Gonzalez, L Zalewski, C Albor, ... Přejít k původnímu zdroji... Přejít na PubMed, 0 | 9 | |
| Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD M Schroeder-Castagno, A Del Rio-Serrato, A Wilhelm, S Romero-Suárez, ... Journal of Neuroinflammation 19 (1), 239, 2022 | 8 | 2022 |
| Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients K Allen-Philbey, S De Trane, Z Mao, C Álvarez-González, J Mathews, ... Therapeutic advances in neurological disorders 14, 17562864211057661, 2021 | 5 | 2021 |
| Treating multiple sclerosis with generic cladribine C Alvarez-Gonzalez, K Allen-Philbey, J Mathews, M Espasandin, ... | 3 | 2016 |
| Cladribine personalised dosing in people with MS (n> 200)-four years experience in clinical care. S De Trane, Z Mao, C Alvarez-Gonzalez, K Allen-Philbey, O Yildiz, ... | 2 | 2018 |
| PO134 Personalised dosing of cladribine to treat multiple sclerosis Z Mao, C Alvarez-Gonzalez, K Allen-Philbey, J Mathews, BP Turner, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (Suppl 1), A47-A48, 2017 | 2 | 2017 |
| Treating multiple sclerosis with cladribine C Alvarez-Gonzalez, K Allen-Philbey, J Mathews, BP Turner, D Baker, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (12), e1-e1, 2016 | 2 | 2016 |
| Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis N Cerdá-Fuertes, M Stoessel, G Mickeliunas, S Pless, A Cagol, ... Multiple Sclerosis Journal 29 (13), 1540-1550, 2023 | | 2023 |
| Lymphocyte profiles after a first demyelinating event suggestive of multiple sclerosis reveal early monocyte and B cell alterations C Alvarez-Gonzalez, A Wiedemann, M Schroeder-Castagno, S Asseyer, ... medRxiv, 2023.11. 13.23298459, 2023 | | 2023 |
| Deficient response of blood neutrophils to cell death stimuli differentiates AQP4-IgG seropositive NMOSD from MOGAD patients M Schroeder-Castagno, S Romero-Suarez, A Serrato, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 348-349, 2021 | | 2021 |
Klaus SchmiererThe Blizard Institute, Queen Mary University of London, Medicine & Dentistry//Barts Health NHS TrustVerified email at qmul.ac.uk
